CD21L Inhibitors
CD21L inhibitors are chemical compounds that target CD21L, a ligand of CD21, also known as complement receptor 2 (CR2). CD21 is a membrane-bound protein expressed primarily on B cells and follicular dendritic cells and plays an important role in immune system regulation, particularly in the complement system and B cell activation. CD21L refers to the specific ligands that bind to CD21, including fragments of complement component C3d, which enhance the immune response by promoting the interaction between B cells and antigens. Inhibitors of CD21L are designed to interfere with the binding of these ligands to CD21, thereby modulating the signaling pathways associated with antigen recognition and immune activation.
The development of CD21L inhibitors involves designing molecules that can either block the ligand-binding domain on CD21 or competitively bind to CD21L, preventing its interaction with CD21. These inhibitors are typically small molecules, peptides, or biologics engineered to specifically target the interface between CD21 and its ligands. Key aspects of the design process include achieving high specificity for the CD21-CD21L interaction, ensuring that the inhibitors do not affect other related proteins or pathways. Additionally, the inhibitors must exhibit suitable binding affinity and stability to effectively disrupt the ligand-receptor interaction. By inhibiting CD21L, these compounds are used to study the role of the CD21-CD21L interaction in the immune system, providing insights into how this interaction regulates B cell function, immune signaling, and complement-mediated processes across different biological contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Hydrocortisone | 50-23-7 | sc-300810 | 5 g | $100.00 | 6 | |
Hydrocortisone may downregulate CD21L expression by inhibiting transcription factors like AP-1, which are involved in the activation of immune system genes. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol could decrease CD21L levels by enhancing SIRT1 activity, leading to the deacetylation and suppression of transcription factors that promote CR2 gene expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin may reduce CD21L expression through targeted inhibition of mTOR signaling pathways, resulting in decreased B-cell development and function. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporin A could inhibit CD21L production by preventing the transcription of IL-2, a cytokine necessary for T-cell assisted B-cell activation which induces CR2 expression. | ||||||
Aspirin | 50-78-2 | sc-202471 sc-202471A | 5 g 50 g | $20.00 $41.00 | 4 | |
Aspirin may decrease CD21L expression by irreversibly inhibiting COX enzymes, leading to lowered prostaglandin synthesis and subsequent downregulation of inflammatory pathways that stimulate CR2 gene expression. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin could suppress CD21L transcription by inhibiting the phosphorylation of transcription factors such as STAT3, which are implicated in the expression of genes during immune responses. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
Epigallocatechin Gallate could downregulate CD21L by hindering the activity of DNA methyltransferases, potentially leading to hypermethylation of the CR2 gene promoter, which silences gene expression. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $56.00 | 1 | |
Hydroxychloroquine may reduce CD21L expression by accumulating in lysosomes, altering pH, and thereby disrupting antigen presentation and subsequent B-cell activation that would normally upregulate CR2 expression. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Methotrexate could decrease the levels of CD21L by inhibiting dihydrofolate reductase, leading to reduced nucleotide synthesis and a subsequent drop in the proliferation of B-cells that express CR2. | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $68.00 $261.00 | 8 | |
Mycophenolic acid might inhibit the production of CD21L by blocking purine synthesis, which is essential for B-cell growth and differentiation, processes necessary for the maintenance of CR2 expression levels. | ||||||